Diabetes - A common, growing, serious, costly, and potentially preventable public health problem

Diabetes Research and Clinical Practice

Volumn 50, Issue SUPPL. 2, 2000, Pages

  Narayan, K M Venkat ^a   Gregg, Edward W ^a   Fagot Campagna, Anne ^a   Engelgau, Michael M ^a   Vinicor, Frank ^a  

^a NATIONAL CENTER FOR CHRONIC DISEASE PREVENTION AND HEALTH PROMOTION   (United States)

Author keywords

Cost; Diabetes; Prevalence; Prevention; Public health; Quality of care

Indexed keywords

ACETYLSALICYLIC ACID; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR;

BLOOD GLUCOSE MONITORING; BLOOD PRESSURE REGULATION; DIABETES MELLITUS; DIABETIC RETINOPATHY; DIETARY INTAKE; HIGH RISK POPULATION; HUMAN; INSULIN RESISTANCE; OBESITY; PHYSICAL ACTIVITY; PREVALENCE; PUBLIC HEALTH; REVIEW;

EID: 0033807778     PISSN: 01688227     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0168-8227(00)00183-2     Document Type: Article

References (46)

1. F. Vinicor, Is diabetes a public-health disorder?, Diabetes Care 17 (Suppl. 1) (1994) 22-27.
2. H. King, R.E. Aubert, W.H. Herman, Global burden of diabetes, 1995-2025: prevalence, numerical estimates, and projections, Diabetes Care 21 (1998) 1414-1431.
3. A. Fagot-Campagna, D.J. Pettitt, M.M. Engelgau, N.R. Burrows, L.S. Geiss, R. Valdez, G. Beckles, J. Saaddine, E.W. Gregg, D.F. Williamson, K.M.V. Narayan, Type 2 diabetes among North American children and adolescents: an epidemiological review and a public health perspective, J. Pediatr. 136 (2000) 664-672.
4. International Diabetes Federation Task Force on Diabetes Health Economics, Diabetes health economics: facts, figures, and forecasts, International Diabetes Federation, Brussels, 1997.
5. Centers for Disease Control and Prevention, Diabetes surveillance 1997, Atlanta Department of Health and Human Services, 1997.
6. J.B. Saddinne, K.M.V. Narayan, M.M. Engelgau, R.E. Aubert, R. Klein, G.L.A. Beckles, Prevalence of self-rated visual impairment among adults with diabetes - United States, 1995, Am. J. Pub. Health 89 (1999) 1200-1205.
7. M.I. Harris, Summary, in: National Diabetes Data Group. Diabetes in America (NIH publication no. 95-1468), 2nd edn., Government Printing Office, Washington, DC, 1995, pp. 1-14.
8. J.V. Selby, G.T. Ray, D. Zhang, C.J. Colby, Excess costs of medical care for patients with diabetes in a managed care population, Diabetes Care 20 (1997) 1396-1402.
9. R. Shobhana, P.R. Rao, A. Lavanya, R. Williams, V. Vijay, A. Ramachandran, Expenditure on health care incurred by diabetic subjects in a industrializing country - a study from southern India, Diabetes Res. Clin. Pract. (2000) in press.
10. W.C. Knowler, D.J. Pettitt, M.F. Saad, P.H. Bennett, Diabetes mellitus in the Pima Indians: incidence, risk factors and pathogenesis, Diabetes/Metab. Rev. 6 (1990) 1-27.
11. J.P. Burke, K. Williams, S.P. Gaskill, H.P. Hazuda, S.M. Haffner, M.P. Stern, Rapid rise in the incidence of type 2 diabetes from 1987 to 1996, Arch. Intern. Med. 159 (1999) 1450-1456.
12. W.C. Knowler, K.M.V. Narayan, R.L. Hanson, R.G. Nelson, P.H. Bennett, J. Tuomilehto, B. Scherstén, D.J. Pettitt, Preventing non-insulin-dependent diabetes mellitus, Diabetes 44 (1995) 483-488.
13. K.-F. Eriksson, F. Lindgarde, Prevention of type 2 (non-insulin-dependent) diabetes mellitus by diet and physical exercise: the 6-year Malmo feasibility study, Diabetologia 34 (1991) 891-898.
14. X. Pan, G. Li, Y. Hu, J. Wang, W. Yang, Z. An, Z. Hu, J. Lin, J. Xiao, H. Cao, P. Liu, X. Jiang, Y. Jiang, J. Wang, H. Zheng, H. Zhang, P.H. Bennett, B.V. Howard, Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance: the Da Qing IGT and Diabetes Study, Diabetes Care 20 (1997) 537-544.
15. The Diabetes Prevention Program Research Group, The Diabetes Prevention Program: design and methods for a clinical trial in the prevention of type 2 diabetes, Diabetes Care 22 (1999) 623-634.
16. J. Eriksson, J. Lindstorm, T. Valle, S. Aunola, H. Hamalainen, P. Hanne-Parikka, S. Keinanen-Kiukaanniemi, M. Laakso, M. Lauhnkonen, P. Lehoto, A. Lehtonen, et al. on behalf of the Finnish Diabetes Prevention Study Group. Prevention of type II diabetes in subjects with impaired glucose tolerance: the Diabetes Prevention Study (DPS) in Finland, Diabetologia 42 (1999) 793-801.
17. J.L. Chiasson, R. Gomis, M.H. Hanefeld, R.G. Josse, A. Karasik, M. Laakso, The STOP-NIDDM Trial Research Group, Diabetes Care 21 (1998) 1720-1725.
18. M.M. Engelgau, K.M.V. Narayan, The evidence to screen for type 2 diabetes, in: R. Williams (Ed.), The Evidence Base for Diabetes Care, Wiley, UK (in press).
19. The Diabetes Control and Complications Trial Research Group, The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus, N. Engl. J. Med. 329 (1993) 977-986.
20. The UK Prospective Diabetes Study (UKPDS) Group, Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complication in-patients with type 2 diabetes (UKPDS 33), Lancet 352 (1998) 837-853.
21. The UK Prospective Diabetes Study (UKPDS) Group, Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes (UKPDS 38), Br. Med. J. 317 (1998) 703-713.
22. J.D. Curb, S.L. Pressel, J.A. Cutler, P.J. Savage, W.B. Applegate, H. Black, G. Camel, B.R. Davis, P.H. Frost, N. Gonzalez, G. Guthrie, A. Oberman, G.H. Rutan, J. Stamler, Effect of diuretic-based antihypertensive treatment on cardiovascular disease risk in older diabetic patients with isolated systolic hypertension. Systolic Hypertension in the Elderly Program Cooperative Research Group, J. Am. Med. Assoc. 276 (1996) 1886-1892.
23. K. Pyorala, T.R. Pedersen, J. Kjekshus, O. Faergeman, A.G. Olsson, G. Thorgeirsson, Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease. A subgroup analysis of the Scandinavian Simvastatin Survival Study (4S), Diabetes Care 210 (1997) 614-620.
24. R.B. Goldberg, M.J. Mellies, F.M. Sacks, L.A. Moye, W.J. Howard, B.R. Davis, T.G. Cole, M.A. Pfeffer, E. Braunwald, Cardiovascular events and their reduction with pravastatin in diabetic and glucose-intolerant myocardial infarction survivors with average cholesterol levels. Subgroup analyses in the Cholesterol and recurrent Events (CARE) Trial, Circulation 98 (1998) 2513-2519.
25. ETDRS Investigators, Aspirin effects on mortality and morbidity in patients with diabetes mellitus. Early Treatment Diabetic Retinopathy Study Report 14, J. Am. Med. Assoc. 268 (1992) 1292-1300.
26. Antiplatelet Trialists' Collaboration, Collaborative overview of randomized trials of antiplatelet therapy, I: prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients, Br. Med. J. 308 (1994) 81-106.
27. M. Ravid, R. Lang, R. Rachmani, M. Lishner, Longterm renoprotective effect of angiotensin- converting enzyme inhibition in non-insulin dependent diabetes mellitus: a 7-year follow-up study, Arch. Intern. Med. 156 (1996) 286-289.
28. The Health Outcomes Prevention Evaluation Study Investigators, Effects of an angiotensin-converter enzyme inhibitor, Ramipril, on death from cardiovascular causes, myocardial infarction and stroke in high-risk patients, N. Engl. J. Med. 342 (2000) 145-153.
29. Early Treatment Diabetic Retinopathy Study (ETDRS) Research Group, Early photocoagulation for diabetic retinopathy: ETDRS report number 9, Ophthalmology (Suppl.) 98 (1991) 767-785.
30. D.K. Littzelman, C.W. Slemenda, C.D. Langefeld, L.M. Hays, M.A. Welch, D.E. Bild, E.S. Ford, F. Vinicor, Reduction of lower extermity clinical abnormalities in patients with non-insulin-dependent diabetes mellitus: a randomized controlled trial, Ann. Intern. Med. 119 (1993) 36-41.
31. C.J. McCabe, R.C. Stevenson, A.M. Dolan, Evaluation of a diabetic foot screening and protection programme, Diabet. Med. 15 (1998) 80-84.
32. K.L. Nichol, J. Wuorenma, T. von Sternberg, Benefits of influenza vaccination for low-,intermediate-, and high risk senior citizens, Arch. Intern. Med. 158 (1998) 1769-1776.
33. The Diabetes Control and Complications Trial Research Group, Lifetime benefits and costs of intensive therapy as practices in the Diabetes Control and Complications Trial, J. Am. Med. Assoc. 276 (1996) 1409-1415.
34. The UK Prospective Diabetes Study (UKPDS) Group, Cost effectiveness analysis of improved blood pressure control in hypertensive patients with type 2 diabetes: UKPDS 40, Br. Med. J. 317 (1998) 720-726.
35. J.S. Schwartz, S.J. Boccuzzi, H. Glick, J.R. Cook, B. Kinosian, T.R. Pedersen, J. Kjekshus, Cost effectiveness of LDL-C reduction in diabetic CHD patients:implications from the Scandinavian Simvastatin Survival Study (4S), Circulation 96 (Suppl. 1) (1997) 1504-1505.
36. J.C. Javitt, L.P. Aiello, Y.P. Chiang, F.L. Ferris, J.K. Canner, S. Greenfield, Preventative eye care in people with diabetes is cost-saving to the federal government, Diabetes Care 17 (1994) 909-917.
37. J.E. Siegel, A.S. Krolewski, J.H. Warram, M.C. Weinstein, Cost-effectiveness of screening and early treatment of nephropathy in patients with insulin-dependent diabetes mellitus, J. Am. Soc. Nephrol. (Suppl.) 3 (1992) 111-119.
38. B.A. Kiberd, K.K.J. indal, Screening to prevent renal failure in insulin dependent diabetic patients: an economic evaluation, Br. Med. J. 311 (1995) 1595-1599.
39. M.I. Harris, R.C. Eastman, C.C. Cowie, K.M. Flegal, M.S. Eberhardt, Racial and ethnic differences in glycemic control of adults with type 2 diabetes, Diabetes Care 22 (1999) 403-408.
40. D. Rolka, A. Fagot-Campagna, V. Narayan, Aspirin use among Americans with diabetes: estimates from NHANES III (abstract), Diabetes 48 (Suppl. 1) (1999) A41.
41. G.L.A. Beckles, M.M. Engelgau, K.M.V. Narayan, W.H. Herman, R.E. Aubert, D.F. Williamson, Population-based assessment of the level of care among adults with diabetes in the US, Diabetes Care 21 (1998) 1432-1438.
42. Centers for Disease Control and Prevention, Influenza and pneumococcal vaccination rates among persons with diabetes mellitus - United States, 1997. MMWR 48 (1999) 961-7.
43. American Diabetes Association, Clinical practice recommendations, Diabetes Care 22 (Suppl. 1) (1999).
44. National Committee on Quality Assurance. Available at www.ncqa.org.
45. The CDC Diabetes in Managed Care Work Group, Exploring and expanding the research agenda for diabetes in managed care: a report of a Centers for Disease Control and Prevention - Managed Care workshop, Diabetes Care 22 (1999) 1734-1738.
46. Centers for Disease Control and Prevention, Program announcement number 98086, Translation Research Centers for Diabetes Control within Managed-care Settings, Atlanta, CDC, 1998.